Cargando…

Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants

BACKGROUND AND OBJECTIVES: Nonadherence to oral immunosuppressive drugs in renal transplant patients remains a major challenge. The objective of this study was to develop an adherence-exposure model that 1) quantifies the impact of nonadherence patterns on cyclosporine levels and 2) identifies nonad...

Descripción completa

Detalles Bibliográficos
Autores principales: Maclean, J Ross, Pfister, Marc, Zhou, Zexun, Roy, Amit, Tuomari, Vickie A, Heifets, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116802/
https://www.ncbi.nlm.nih.gov/pubmed/21691585
http://dx.doi.org/10.2147/TCRM.S16870
_version_ 1782206277662801920
author Maclean, J Ross
Pfister, Marc
Zhou, Zexun
Roy, Amit
Tuomari, Vickie A
Heifets, Michael
author_facet Maclean, J Ross
Pfister, Marc
Zhou, Zexun
Roy, Amit
Tuomari, Vickie A
Heifets, Michael
author_sort Maclean, J Ross
collection PubMed
description BACKGROUND AND OBJECTIVES: Nonadherence to oral immunosuppressive drugs in renal transplant patients remains a major challenge. The objective of this study was to develop an adherence-exposure model that 1) quantifies the impact of nonadherence patterns on cyclosporine levels and 2) identifies nonadherence patterns that are associated with unfavorable transplantation outcomes. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This model quantified variability in drug exposure, expressed as the coefficient of variation (CV%), for time-averaged and trough cyclosporine levels (C(avg) and C(min), respectively), and percentage of days spent below the therapeutic C(min) target. Simulated patterns of nonadherence closely matched those observed in clinical practice for four nonadherence clusters and an “Others” category. RESULTS: Patients in simulated nonadherence clusters 1–3 spent a mean (standard deviation) 5.8% (4.9), 9.0% (5.0), and 6.5% (3.4) of days below the C(min) target, compared with 76.8% (6.5) for cluster 4 and 38.3% (6.4) for the “Others” category. Mean (standard deviation) CV% values for C(min) were 24.1 (7.9), 35.4 (11.7), and 34.1 (10.6) for clusters 1–3, compared with 136.4 (23.6) for cluster 4 and 64.8 (10.3) for the “Others” category. Findings for C(avg) were similar. CONCLUSION: Based on nonadherence patterns and known relationships between CV% for C(min) and C(avg), and transplantation outcomes, patients in cluster 4 and the “Others” category are expected to be at high risk of allograft rejection. The proposed drug adherence-exposure model is useful to identify high-risk patients who can be targeted for interventions aimed at enhancing drug adherence to optimize clinical long-term outcomes.
format Online
Article
Text
id pubmed-3116802
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31168022011-06-20 Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants Maclean, J Ross Pfister, Marc Zhou, Zexun Roy, Amit Tuomari, Vickie A Heifets, Michael Ther Clin Risk Manag Original Research BACKGROUND AND OBJECTIVES: Nonadherence to oral immunosuppressive drugs in renal transplant patients remains a major challenge. The objective of this study was to develop an adherence-exposure model that 1) quantifies the impact of nonadherence patterns on cyclosporine levels and 2) identifies nonadherence patterns that are associated with unfavorable transplantation outcomes. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This model quantified variability in drug exposure, expressed as the coefficient of variation (CV%), for time-averaged and trough cyclosporine levels (C(avg) and C(min), respectively), and percentage of days spent below the therapeutic C(min) target. Simulated patterns of nonadherence closely matched those observed in clinical practice for four nonadherence clusters and an “Others” category. RESULTS: Patients in simulated nonadherence clusters 1–3 spent a mean (standard deviation) 5.8% (4.9), 9.0% (5.0), and 6.5% (3.4) of days below the C(min) target, compared with 76.8% (6.5) for cluster 4 and 38.3% (6.4) for the “Others” category. Mean (standard deviation) CV% values for C(min) were 24.1 (7.9), 35.4 (11.7), and 34.1 (10.6) for clusters 1–3, compared with 136.4 (23.6) for cluster 4 and 64.8 (10.3) for the “Others” category. Findings for C(avg) were similar. CONCLUSION: Based on nonadherence patterns and known relationships between CV% for C(min) and C(avg), and transplantation outcomes, patients in cluster 4 and the “Others” category are expected to be at high risk of allograft rejection. The proposed drug adherence-exposure model is useful to identify high-risk patients who can be targeted for interventions aimed at enhancing drug adherence to optimize clinical long-term outcomes. Dove Medical Press 2011 2011-04-11 /pmc/articles/PMC3116802/ /pubmed/21691585 http://dx.doi.org/10.2147/TCRM.S16870 Text en © 2011 Maclean et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Maclean, J Ross
Pfister, Marc
Zhou, Zexun
Roy, Amit
Tuomari, Vickie A
Heifets, Michael
Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title_full Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title_fullStr Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title_full_unstemmed Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title_short Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
title_sort quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116802/
https://www.ncbi.nlm.nih.gov/pubmed/21691585
http://dx.doi.org/10.2147/TCRM.S16870
work_keys_str_mv AT macleanjross quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants
AT pfistermarc quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants
AT zhouzexun quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants
AT royamit quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants
AT tuomarivickiea quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants
AT heifetsmichael quantifyingtheimpactofnonadherencepatternsonexposuretooralimmunosuppressants